Send to

Choose Destination
Br J Cancer. 2016 Nov 8;115(10):1215-1222. doi: 10.1038/bjc.2016.343. Epub 2016 Oct 20.

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.

Author information

Klinikum Neuperlach/Klinikum Harlaching, Oskar-Maria-Graf-Ring 51, D81737 Munich, Germany.
Universitätsmedizin Mannheim, Theodor-Kutzer Ufer 1-3, 68167 Mannheim, Germany.
Institut Sainte-Catherine GI and Liver Cancer Unit, 84 000 Avignon, France.
Oncology Clinic, Västmanland's Hospital, 721 89 Västerås, Sweden.
IIIrd Medical Department, Paracelsus Medical University Salzburg and CCCIT Salzburg Cancer Research Institute, Müllner Hauptstrasse 45, 5020 Salzburg, Austria.
Klinikum Wels-Grieskirchen, Grieskirchner Straße 42, A-4600 Wels, Austria.
Central Hospital, Strandvägen 8, 35185 Växjö, Sweden.
Formerly of Amgen Inc., 1 Amgen Center Dr MS 30E-2-C, Thousand Oaks, CA 91320, USA.
Amgen Inc., 1 Amgen Center Dr MS 30E-2-C, Thousand Oaks, CA 91320, USA.
Amgen GmbH, Dammstrasse 23, 6301 Zug, Switzerland.
Onkologie Klinikum Oldenburg, Rahel-Straus-Str. 10, 26133 Oldenburg, Germany.



To investigate tumour biomarker status and efficacy of first-line panitumumab+FOLFIRI for metastatic colorectal carcinoma (mCRC).


154 patients received first-line panitumumab + FOLFIRI every 14 days. Primary end point was objective response rate (ORR). Data were analysed by tumour RAS (KRAS/NRAS) and BRAF status, and baseline amphiregulin (AREG) expression.


Objective responses occurred more frequently in RAS wild type (WT) (59%) vs RAS mutant (MT) (41%) mCRC and in RAS WT/BRAF WT (68%) vs RAS or BRAF MT (37%) disease. Median response duration was longer in RAS WT (13.0 months) vs RAS MT (5.8 months) (hazard ratio (HR): 0.16). Median progression-free survival was longer in RAS WT vs MT (11.2 vs 7.3 months; HR, 0.37) and was also longer in RAS WT/BRAF WT vs RAS or BRAF MT (13.2 vs 6.9 months; HR, 0.25). Incidence of adverse events was similar regardless of RAS/BRAF status, and no new safety signals were noted. Among patients with RAS WT tumours, ORR was 67% with high AREG expression and 38% with low AREG expression.


First-line panitumumab+FOLFIRI was associated with favourable efficacy in patients with RAS WT and RAS WT/BRAF WT vs MT mCRC tumours and was well tolerated.

[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

MK is an advisor for, and has received honoraria from, Amgen Ltd. R-DH has received honoraria from Amgen Ltd. LM is an advisor for, and has received honoraria and research funding from, Amgen. HL has acted as a consultant/advisor for Amgen Ltd & Roche Ltd. RG has received research support from Amgen. JT has received honoraria and research funding from Amgen Ltd. KSO is a former employee of Amgen Inc. MB, BT, YZ, GD are employees of Amgen Inc. C-HK has acted as a consultant/advisor to Amgen Ltd, Merck KG Darmstadt & Roche Ltd. EF declares no conflict of interest.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center